Tauklarify is a PET imaging agent, approved by the FDA on August 14, 2026, that binds to tau tangles in the brain to help evaluate Alzheimer's disease, while blood tests measuring p-tau217 and related tau markers screen for the same disease from a vein draw. Both are established tools for people with mild cognitive impairment, and the current evidence shows they answer different questions rather than one simply replacing the other. For someone with mild cognitive impairment (MCI), the practical pattern emerging from 2026 research is blood testing first, PET imaging second. The two methods agree closely at a population level, but each has situations where it outperforms the other, and cost pushes the decision in a specific direction.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Tauklarify Actually Does and Who Qualifies
- How Blood Tests Compare on Accuracy
- Cost and Access Differences That Shape the Decision
- A Practical Path for Someone With MCI
- Frequently Asked Questions
What Tauklarify Actually Does and Who Qualifies
Tauklarify (florquinitau F-18) is an injectable radioactive tracer that attaches to tau neurofibrillary tangles, the twisted protein threads inside neurons that accumulate as Alzheimer's progresses. A PET scanner then images where the tracer has bound, giving a visual map of tau buildup in the brain. The FDA approved it for adults with cognitive impairment who are being evaluated for Alzheimer's disease, and it became only the second tau tracer ever approved, after Tauvid. Approval rested on two blinded reader studies covering more than 500 subjects with MCI, mild Alzheimer's dementia, and no cognitive impairment.
Readers using Tauklarify scans agreed with a clinical reference standard 80-88% of the time in the first study and 68-82% of the time in the second, according to Lantheus's data reported by Applied Radiology. That range means the scan is a strong but imperfect signal, not a yes-or-no answer on its own. Side effects were uncommon across the 1,734 subjects studied: headache in 0.7%, nausea in 0.2%, and injection-site reaction in 0.1%. The FDA has not established that Tauklarify works for evaluating tauopathies other than Alzheimer's, so it isn't a general-purpose tool for every condition involving abnormal tau.
How Blood Tests Compare on Accuracy
Plasma p-tau217, a fragment of the tau protein measured in a standard blood draw, has moved from research tool to clinical signal over the past two years. A Nature Aging study following 1,534 cognitively unimpaired adults across nine cohorts found that p-tau217, medial-temporal tau-PET, and neocortical tau-PET each predicted later cognitive decline about equally well, with no method significantly outperforming the others. A separate JAMA Neurology study published May 26, 2026, tested a blood model measuring two circulating tau forms in more than 1,000 people across the Alzheimer's spectrum, including those with MCI. The disease stage the blood test produced closely matched the stage derived from PET scans, according to coverage of the JAMA Neurology findings.
A pooled analysis of nearly 2,700 participants presented at the Alzheimer's Association International Conference 2026 added a longer-range figure: people with p-tau217 above twice the study average faced an estimated 38% five-year and 78% ten-year risk of progressing to cognitive impairment, even after accounting for amyloid PET results, per the JAMA/AAIC analysis. Blood testing isn't flawless at every stage. A study of 99 cognitively unimpaired adults found blood-based markers had limited sensitivity when tau pathology was still extremely subtle, suggesting PET keeps an edge for catching the very earliest, lowest-burden disease. A 57-participant Karolinska Institutet study similarly found tau-PET correlated more strongly with cognitive impairment than the blood marker, particularly in early-onset disease, though the researchers described this as a cross-sectional finding needing confirmation in larger, longitudinal studies.
Cost and Access Differences That Shape the Decision
Price separates the two tools sharply. Tau-PET scanning runs roughly $5,000-$6,000 per scan, while plasma p-tau217 testing costs around $200-$400, according to a cost comparison in The Carlat Report. That gap alone makes blood testing the more realistic first step for most people with MCI, especially when insurance coverage for PET imaging is uncertain or requires prior authorization.
A memory-clinic analysis found that using plasma p-tau217 at a 95%-sensitivity cutoff would have avoided nearly half of tau-PET scans that would otherwise have been ordered. Among patients still referred for a scan under that strategy, roughly 70% turned out to be tau-PET positive, meaning the blood test successfully screened out many people who didn't need imaging while preserving most of the true positive cases for confirmation. This points to blood testing as a triage step rather than a replacement. A low p-tau217 result makes a PET scan less urgent; a high or ambiguous result is where PET earns its cost, either confirming the biological basis of MCI symptoms or resolving a case where the blood result alone leaves genuine uncertainty.
A Practical Path for Someone With MCI
For a patient or caregiver weighing these options, the sequence suggested by the evidence looks like this: Neither test eliminates the other from the diagnostic picture. The two methods agree closely across large study populations, but the remaining disagreement, concentrated at the earliest and most subtle stages of tau buildup, is exactly where a clinician's choice between a $300 blood draw and a $5,000 scan matters most.
- Start with a plasma p-tau217 test if a clinician offers one, since it costs a fraction of PET imaging and performs comparably for most purposes.
- Treat a clearly low result as reassuring, since the memory-clinic data showed it correctly ruled out many people who did not need a scan.
- Ask about tau-PET, such as Tauklarify, when the blood result is high, borderline, or inconsistent with the clinical picture, since PET gives a direct anatomical read rather than a blood-based inference.
- Expect PET to matter more at the earliest, lowest-burden stage of disease, where some evidence suggests blood tests are less sensitive.
- Confirm with the ordering clinician whether a specific Alzheimer's diagnosis, rather than a general tauopathy question, is what's being evaluated, since Tauklarify's approval does not extend to other tau-related conditions.
Frequently Asked Questions
Is Tauklarify the same thing as a blood test for Alzheimer's?
No. Tauklarify is an injected PET imaging tracer that produces a brain scan, while p-tau217 tests analyze a blood sample; they measure tau through different methods and at different costs.
Can a blood test replace a PET scan entirely for someone with MCI?
Not based on current evidence. Blood testing can rule out many unnecessary scans, but a 57-participant Karolinska study found PET still correlated more strongly with cognitive impairment, particularly in early-onset cases.
Does insurance typically cover Tauklarify scans?
The research packet doesn't address coverage specifics; the approval and performance data concern clinical accuracy, not insurance policy, so that question is best directed to the ordering clinic.
You Might Also Like
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment
